Aspen Pharmacare Earnings Jump 22% on Mounjaro Demand

Original Article by Tamar Kahn | Business Day | 3 September 2026

Aspen Pharmacare earnings rose 22% as demand for Eli Lilly's weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.

Image | Ole Schwander | Shutterstock/2387881597

Aspen Pharmacare earnings rose 22% as demand for Eli Lilly’s weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.

Subscription Required

You must be a subscriber to access all of this content.

Already a subscriber? Log in here

Discovery Group results for 2026 show profit up 17% to R17.75bn, driven by Discovery Health, the Bank’s turnaround and global Vitality growth.

Mandatory medical scheme membership for taxpayers could cut cover costs by up to 30%, HFA research finds, alongside a risk equalisation fund.

The 2025 Mediscor Medicines Review shows medicine spend up 4.7%, with generics, chronic care and speciality drugs shaping affordability.